CDMO Rentschler Biopharma has chosen Commodore Builders to help build its new production site in the US that will feature 22,000 sqft of cleanroom space to be Industry 4.0 enabled
CDMO Rentschler Biopharma has broken ground at its new production site, adjacent to its existing site in Milford, MA in the greater Boston area.
The new Rentschler Biopharma Manufacturing Center US (RBMC US) will add 22,000 sqft of manufacturing cleanroom space and house four new 2,000 L single-use bioreactors.
Commodore Builders has been chosen to help build the manufacturingWe’re thrilled to be part of expanding Massachusetts’ life sciences capacity!
In keeping with Rentschler Biopharma's commitment to reducing the complexity of biopharmaceutical manufacturing for its clients, the site is designed to be easily adaptable to meet clients' changing needs. The RBMC US is expected to become operational in late 2023.
The design features upstream ballroom processing sized for production flexibility. The downstream processing suites are equipped with buffer storage and preparation space.
It will provide innovative digital and analytical services, such as advanced analytics yield optimisation, augmented/virtual reality-enabled operations and no-touch batch releases
The building design can accommodate future adaptations for scale and capacity. Growing with the manufacturing footprint, the site will include expanded quality control (QC), development, and warehousing capabilities. Importantly, this new state-of-the-art facility will also be highly automated and leverage industry 4.0 solutions. It will provide innovative digital and analytical services, such as advanced analytics yield optimisation, augmented/virtual reality-enabled operations and no-touch batch releases.
Dr Frank Mathias, CEO of Rentschler Biopharma SE, said: "The US expansion we have kicked off at the groundbreaking is part of our ongoing plan to strategically grow our business as we support our clients in developing and manufacturing even highly complex molecules. We must always be ready to meet the ongoing and ever-changing challenges of reliably bringing new treatments to patients."
Dr Martin Kessler, CEO of Rentschler Biopharma, the wholly-owned US subsidiary, added: "This new site will double our commercial cGMP manufacturing capacity. By bringing in state-of-the-art technology and industry 4.0 solutions, RBMC US will strongly enhance our value proposition in commercial manufacturing."
The new site will significantly expand the company's US offering in terms of capacity and diversity of projects. The current Milford site has gone from a single-product commercial facility to producing multiple products in up to 500 L bioreactor set up.
The new facility will add much-needed space for manufacturing, as well as enabling US operations to centralise support services that are essential for seamless production.